USRE43932E1
(en)
|
1997-07-18 |
2013-01-15 |
Novartis Ag |
Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
|
CO4940418A1
(es)
*
|
1997-07-18 |
2000-07-24 |
Novartis Ag |
Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
|
ITMI992711A1
(it)
*
|
1999-12-27 |
2001-06-27 |
Novartis Ag |
Composti organici
|
US7087608B2
(en)
*
|
2000-03-03 |
2006-08-08 |
Robert Charles Atkins |
Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
|
SK287335B6
(sk)
*
|
2000-10-27 |
2010-07-07 |
Novartis Ag |
Použitie 4-{(4-metylpiperazin-1-ylmetyl)-N-[4-metyl-3-(4-pyrid-3- yl)pyrimidin-2-ylamino]fenyl}-benzamidu na prípravu farmaceutických kompozícií na liečenie gastrointestinálnych strómových tumorov
|
NZ527692A
(en)
|
2001-02-19 |
2005-05-27 |
Novartis Ag |
Cancer treatment
|
RU2313345C2
(ru)
*
|
2001-02-27 |
2007-12-27 |
Новартис Аг |
Комбинации, содержащие ингибитор трансдукции сигнала и производное эпотилона
|
GB0108606D0
(en)
*
|
2001-04-05 |
2001-05-23 |
Novartis Ag |
Organic compounds
|
AU2005246965B2
(en)
*
|
2001-05-16 |
2008-04-17 |
Novartis Ag |
Combination comprising N-{5-[4(4-methyl-piperazino-methyl)-bezoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
|
SI1392313T1
(sl)
*
|
2001-05-16 |
2007-08-31 |
Novartis Ag |
Kombinacija, ki vkljuäśuje n-5-4-(4-metil-piperazino-metil)-benzoilamido/-2-metilfenil-4-(3- piridil)-2pirimidin-amin in difosfonat
|
EP1704863A3
(de)
*
|
2001-05-16 |
2010-11-24 |
Novartis AG |
Kombination von N-{5-[4-(4-Methyl-Piperazino-Methyl)-Benzoylamido]-2-Methylphenyl}-4-(3-Pyridyl)-2Pyrimidine-Amin mit einem Chemotherapeutikum
|
CA2450473C
(en)
|
2001-06-14 |
2011-11-15 |
The Regents Of The University Of California |
Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571
|
AU2002315388A1
(en)
*
|
2001-06-21 |
2003-01-08 |
Ariad Pharmaceuticals, Inc. |
Novel phenylamino-pyrimidines and uses thereof
|
JP2004537537A
(ja)
|
2001-06-29 |
2004-12-16 |
アブ サイエンス |
炎症性疾患を治療するためのチロシンキナーゼ阻害剤の使用法
|
JP2004537542A
(ja)
|
2001-06-29 |
2004-12-16 |
アブ サイエンス |
炎症性腸疾患(ibd)を治療するための、チロシンキナーゼ阻害剤の使用
|
DE60223063T2
(de)
|
2001-06-29 |
2008-07-17 |
Ab Science |
C-kit inhibitoren
|
JP2004537536A
(ja)
|
2001-06-29 |
2004-12-16 |
アブ サイエンス |
アレルギー疾患を治療するためのチロシンキナーゼ阻害剤の使用方法
|
WO2003013540A1
(en)
|
2001-08-10 |
2003-02-20 |
Novartis Ag |
Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
|
GB0120690D0
(en)
|
2001-08-24 |
2001-10-17 |
Novartis Ag |
Organic compounds
|
JP2005511596A
(ja)
*
|
2001-09-20 |
2005-04-28 |
アブ サイエンス |
ヒトの皮膚を白くし、且つメラノサイト機能不全関連疾病を治療するためのチロシンキナーゼ阻害剤の使用方法
|
EP2290056A3
(de)
|
2001-10-05 |
2011-06-01 |
Novartis AG |
Mutante der kinase domäne des abl
|
US7045523B2
(en)
|
2001-10-18 |
2006-05-16 |
Novartis Ag |
Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and telomerase inhibitor
|
WO2003034938A2
(en)
*
|
2001-10-25 |
2003-05-01 |
Wisconsin Alumni Research Foundation |
Vascular stent or graft coated or impregnated with protein tyrosine kinase inhibitors and method of using same
|
GB0127922D0
(en)
*
|
2001-11-21 |
2002-01-16 |
Novartis Ag |
Organic compounds
|
GB0201508D0
(en)
|
2002-01-23 |
2002-03-13 |
Novartis Ag |
Organic compounds
|
AU2007201056B2
(en)
*
|
2002-01-28 |
2010-06-10 |
Hyks-Instituutti Oy |
Treatment of rheumatoid arthritis using imatinib
|
GB0201882D0
(en)
*
|
2002-01-28 |
2002-03-13 |
Novartis Ag |
Organic compounds
|
GB0202873D0
(en)
|
2002-02-07 |
2002-03-27 |
Novartis Ag |
Organic compounds
|
WO2003070248A1
(en)
*
|
2002-02-22 |
2003-08-28 |
The Government Of The United States The Department Of Veterans Affairs |
Use of 4-(4-methylpiperazin-1-ylmethyl)-n[4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl]-benzamide for treating seminomas
|
US20050209244A1
(en)
*
|
2002-02-28 |
2005-09-22 |
Prescott Margaret F |
N{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents
|
DE60308337T2
(de)
*
|
2002-03-15 |
2007-09-20 |
Novartis Ag |
4-(4-Methylpiperazin-1-ylmethyl)-N-(4-methyl-3-(4-pyrimidin-3-yl)pyrimidin-2-ylamino)phenylbenzamid zur Behandlung von Ang II vermitteltern Erkrankungen
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
AU2003226209B2
(en)
*
|
2002-03-21 |
2008-10-23 |
Dana-Farber Cancer Institute, Inc. |
Inhibition of cell death responses induced by oxidative stress
|
WO2003086497A1
(en)
*
|
2002-04-16 |
2003-10-23 |
Issam Moussa |
Drug eluting vascular stent and method of treating hyperproliferative vascular disease
|
AU2007201830C1
(en)
*
|
2002-04-23 |
2017-09-07 |
Novartis Pharma Ag |
High drug load tablet
|
GB0209265D0
(en)
*
|
2002-04-23 |
2002-06-05 |
Novartis Ag |
Organic compounds
|
CA2483594C
(en)
|
2002-05-16 |
2011-02-15 |
Novartis Ag |
Use of edg receptor binding agents in cancer
|
US20060052387A1
(en)
*
|
2002-06-26 |
2006-03-09 |
Marsh Clay B |
Organic compounds
|
CA2487356A1
(en)
*
|
2002-06-28 |
2004-01-08 |
The Administrators Of The Tulane Educational Fund |
4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating pulmonary fibrosis
|
CA2490907C
(en)
*
|
2002-06-28 |
2010-08-24 |
Nippon Shinyaku Co., Ltd. |
Amide derivative
|
JP2005538756A
(ja)
*
|
2002-07-18 |
2005-12-22 |
メドトロニック・エイヴイイー・インコーポレーテッド |
再狭窄を阻害するためのタンパク質−チロシンキナーゼ阻害物質を含んでなる医療デバイス
|
CA2492878A1
(en)
*
|
2002-07-19 |
2004-01-29 |
Ludwig Institute For Cancer Research |
Enhancing the effect of radioimmunotherapy in the treatment of tumors
|
WO2004009088A1
(en)
*
|
2002-07-24 |
2004-01-29 |
Novartis Ag |
4-(4-methylpiperazin-1-ylmethyl)-n-[4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating anaplastic thyroid cancer
|
JP2005535675A
(ja)
*
|
2002-07-24 |
2005-11-24 |
ユニバーシティ・オブ・シンシナティ |
変異型retキナーゼ関連疾患を処置するための4−(4−メチルピペラジン−1−イルメチル)−n−[4−メチル−3−(4−ピリジン−3−イル)ピリミジン−2−イルアミノ]フェニル]−ベンズアミド
|
CA2494061C
(en)
*
|
2002-07-31 |
2011-06-14 |
Wayne R. Danter |
Protein tyrosine kinase inhibitors
|
US8450302B2
(en)
|
2002-08-02 |
2013-05-28 |
Ab Science |
2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
|
DE60316810T2
(de)
|
2002-08-02 |
2008-07-17 |
Ab Science |
2-(3-aminoaryl)amino-4-aryl-thiazole und ihre verwendung als c-kit inhibitoren
|
CA2439440A1
(en)
|
2002-09-05 |
2004-03-05 |
Emory University |
Treatment of tuberous sclerosis associated neoplasms
|
EP1551824B1
(de)
*
|
2002-10-09 |
2007-12-12 |
Critical Outcome Technologies, Inc. |
Protein-tyrosine-kinase-inhibitoren
|
GB0224455D0
(en)
*
|
2002-10-21 |
2002-11-27 |
Novartis Ag |
Organic compounds
|
WO2004037261A1
(en)
*
|
2002-10-25 |
2004-05-06 |
The Administrators Of The Tulane Educational Fund |
Use of n-‘5-‘4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension
|
US7094785B1
(en)
|
2002-12-18 |
2006-08-22 |
Cornell Research Foundation, Inc. |
Method of treating polycythemia vera
|
GB2398565A
(en)
|
2003-02-18 |
2004-08-25 |
Cipla Ltd |
Imatinib preparation and salts
|
AU2003228014B2
(en)
*
|
2003-04-04 |
2009-11-05 |
Nobil Bio Ricerche S.R.L. |
Vascular stent
|
AU2003232650A1
(en)
|
2003-05-06 |
2004-11-26 |
Il Yang Pharm Co., Ltd. |
N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
|
PE20050158A1
(es)
|
2003-05-19 |
2005-05-12 |
Irm Llc |
Compuestos inmunosupresores y composiciones
|
MY150088A
(en)
|
2003-05-19 |
2013-11-29 |
Irm Llc |
Immunosuppressant compounds and compositions
|
CA2526594C
(en)
*
|
2003-05-27 |
2011-11-08 |
Robert Per Haegerkvist |
Use of tyrosine kinase inhibitors to treat diabetes
|
GB0312086D0
(en)
*
|
2003-05-27 |
2003-07-02 |
Novartis Ag |
Organic compounds
|
TR200504337T1
(tr)
|
2003-06-02 |
2006-12-21 |
Hetero Drugs Limited |
Imatinib mezilat'ın yeni polimorfları
|
EP1635815A4
(de)
*
|
2003-06-03 |
2009-03-25 |
Beth Israel Hospital |
Verfahren und verbindungen zur behandlung von gefässstenose
|
WO2005027971A1
(en)
*
|
2003-09-19 |
2005-03-31 |
Novartis Ag |
Treatment of gastrointestinal stromal tumors with imatinib and midostaurin
|
ATE465731T1
(de)
|
2003-10-23 |
2010-05-15 |
Ab Science |
2-aminoaryloxazol-verbindungen als tyrosinkinase- hemmer
|
MXPA06005598A
(es)
|
2003-11-18 |
2006-08-11 |
Novartis Ag |
Inhibidores de la forma mutante de kit.
|
WO2005063720A1
(ja)
*
|
2003-12-25 |
2005-07-14 |
Nippon Shinyaku Co., Ltd. |
アミド誘導体及び医薬
|
PE20051096A1
(es)
|
2004-02-04 |
2006-01-23 |
Novartis Ag |
Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida
|
HUE028884T2
(en)
|
2004-02-11 |
2017-01-30 |
Natco Pharma Ltd |
A new polymorphic form of imatinib mesylate and a process for its production
|
CN1309719C
(zh)
*
|
2004-02-18 |
2007-04-11 |
陈国庆 |
苯氨基嘧啶衍生物及其用途
|
UA84462C2
(ru)
|
2004-04-02 |
2008-10-27 |
Институт Фармацевтични |
Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой
|
CA2560162C
(en)
|
2004-04-07 |
2013-05-21 |
Novartis Ag |
Inhibitors of iap
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
JP2008504333A
(ja)
*
|
2004-07-01 |
2008-02-14 |
ザ・ネザーランド・キャンサー・インスティテュート |
Bcrp阻害剤および4−(4−メチルピペラジン−1−イルメチル)−n−[4−メチル−3−(4−ピリジン−3−イル)ピリミジン−2−イルアミノ)フェニル]−ベンズアミドを含む、組み合わせ剤
|
WO2006024863A1
(en)
*
|
2004-09-02 |
2006-03-09 |
Cipla Limited |
Stable crystal form of imatinib mesylate and process for the preparation thereof
|
BRPI0515081B8
(pt)
|
2004-09-09 |
2021-05-25 |
Natco Pharma Ltd |
composto, processo para a preparação de um sal de guanidino trifluormetilaroil amida, processo para a preparação de um fenil amino pirido pirimidina, composições farmacêuticas e processos para preparar (3,5-bis trifluormetil)-n-[4-metil-3-(4-piridin-3-il-pirimidin-2-ilamino)-fenil]-benzamida
|
US8735415B2
(en)
|
2004-09-09 |
2014-05-27 |
Natco Pharma Limited |
Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
|
WO2006048890A1
(en)
*
|
2004-11-04 |
2006-05-11 |
Sun Pharmaceutical Industries Limited |
Imatinib mesylate crystal form and process for preparation thereof
|
WO2006054314A1
(en)
*
|
2004-11-17 |
2006-05-26 |
Natco Pharma Limited |
Polymorphic forms of imatinib mesylate
|
JP5197016B2
(ja)
|
2004-12-23 |
2013-05-15 |
デシファラ ファーマスーティカルズ, エルエルシー |
酵素モジュレータ及び治療
|
AU2006231929B2
(en)
|
2005-04-04 |
2012-09-06 |
Ab Science |
Substituted oxazole derivatives and their use as tyrosine kinase inhibitors
|
AU2006242311B2
(en)
|
2005-05-02 |
2010-03-04 |
Novartis Ag |
Use of pyrimidylamimobenzamide derivatives for the treatment of systematic mastocytosis
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
ES2339593T3
(es)
*
|
2005-06-03 |
2010-05-21 |
Novartis Ag |
Combinacion de compuestos de pirimidilaminobenzamida e imatinib para tratar o prevenir enfermedades proliferativas.
|
GT200600316A
(es)
*
|
2005-07-20 |
2007-04-02 |
|
Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
|
KR100674813B1
(ko)
|
2005-08-05 |
2007-01-29 |
일양약품주식회사 |
N-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
|
EP1762230B2
(de)
*
|
2005-08-15 |
2016-04-20 |
Siegfried International AG |
Filmtablette oder Granulat enthaltend ein Pyridylpyrimidin
|
KR20080049766A
(ko)
*
|
2005-08-26 |
2008-06-04 |
노파르티스 아게 |
이마티니브 메실레이트의 델타 및 엡실론 결정 형태
|
EP2275103B1
(de)
|
2005-11-21 |
2014-04-23 |
Novartis AG |
mTOR-Inhibitoren in der Behandlung endokriner Tumore
|
KR20130140909A
(ko)
|
2005-11-25 |
2013-12-24 |
노파르티스 아게 |
이마티니브 메실레이트의 f, g, h, i 및 k 결정형
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
EP2004163B1
(de)
|
2006-04-05 |
2014-09-17 |
Novartis Pharma AG |
Kombination von everolimus und vinorelbin
|
EP2314297A1
(de)
|
2006-04-05 |
2011-04-27 |
Novartis AG |
Kombinationen aus bcr-abl/c-kit/pdgf-r tk-Hemmern zu Krebsbehandlung
|
US7977348B2
(en)
*
|
2006-04-27 |
2011-07-12 |
Sicor Inc. |
Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
|
BRPI0702877A2
(pt)
*
|
2006-04-27 |
2015-07-07 |
Ivax Pharmaceuticals S R O E Teva Pharmaceutical Usa Inc |
Formas polimórficas de mesilato de imatinib, processo para o novo preparo de novas formas cristalinas, amorfas e forma alfa, composições farmacêuticas correlatas, seus processos de preparo e uso
|
US8067421B2
(en)
*
|
2006-04-27 |
2011-11-29 |
Sicor Inc. |
Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
|
US20060223816A1
(en)
*
|
2006-05-08 |
2006-10-05 |
Chemagis Ltd. |
Imatinib mesylate alpha form and production process therefor
|
KR20090007635A
(ko)
|
2006-05-09 |
2009-01-19 |
노파르티스 아게 |
철 킬레이터 및 항-신생물 약제를 포함하는 조합물 및 그의용도
|
US20060223817A1
(en)
*
|
2006-05-15 |
2006-10-05 |
Chemagis Ltd. |
Crystalline imatinib base and production process therefor
|
WO2008004945A1
(en)
*
|
2006-07-04 |
2008-01-10 |
Astrazeneca Ab |
Novel crystalline forms i and ii
|
WO2008004944A1
(en)
*
|
2006-07-04 |
2008-01-10 |
Astrazeneca Ab |
Novel crystalline form ii
|
US8246966B2
(en)
|
2006-08-07 |
2012-08-21 |
University Of Georgia Research Foundation, Inc. |
Trypanosome microsome system and uses thereof
|
CN101951889A
(zh)
*
|
2006-09-01 |
2011-01-19 |
特瓦制药工业有限公司 |
伊马替尼组合物
|
CA2662977A1
(en)
|
2006-09-22 |
2008-03-27 |
Novartis Ag |
Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors
|
ATE502943T1
(de)
|
2006-09-29 |
2011-04-15 |
Novartis Ag |
Pyrazolopyrimidine als pi3k-lipidkinasehemmer
|
EP1988089A1
(de)
|
2006-10-26 |
2008-11-05 |
Sicor, Inc. |
Imatinib-Base und Imatinib-Mesylat und Herstellungsverfahren dafür
|
US20080103305A1
(en)
*
|
2006-10-26 |
2008-05-01 |
Macdonald Peter |
Process for the preparation of imatinib
|
WO2008070350A2
(en)
|
2006-10-27 |
2008-06-12 |
The Board Of Regents Of The University Of Texas System |
Methods and compositions related to wrapping of dehydrons
|
WO2008055966A1
(en)
*
|
2006-11-09 |
2008-05-15 |
Abbott Gmbh & Co. Kg |
Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
|
EP1920767A1
(de)
*
|
2006-11-09 |
2008-05-14 |
Abbott GmbH & Co. KG |
Schmelzverarbeitete Darreichungsform mit Imatinib
|
WO2008066755A2
(en)
|
2006-11-22 |
2008-06-05 |
University Of Georgia Research Foundation, Inc. |
Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents
|
US8138191B2
(en)
|
2007-01-11 |
2012-03-20 |
Critical Outcome Technologies Inc. |
Inhibitor compounds and cancer treatment methods
|
CA2673683C
(en)
|
2007-01-11 |
2014-07-29 |
Critical Outcome Technologies, Inc. |
Compounds and method for treatment of cancer
|
EP2125895B1
(de)
|
2007-02-02 |
2015-04-08 |
Vegenics Pty Ltd |
Vegf-rezeptorantagonisten zur behandlung von allommunität bei organtransplantationen und atherosklerose
|
KR100799821B1
(ko)
*
|
2007-02-05 |
2008-01-31 |
동화약품공업주식회사 |
신규한 이마티닙 캠실레이트 및 그의 제조방법
|
ES2369617T3
(es)
*
|
2007-02-13 |
2011-12-02 |
Ab Science |
Procedimiento para la síntesis de compuestos de 2-aminotiazol como inhibidores de la quinasa.
|
PE20090519A1
(es)
|
2007-02-15 |
2009-05-29 |
Novartis Ag |
Composicion farmaceutica que contiene n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)-etil]-amino]-metil]-fenil]-2e-2-propenamida
|
CN101323629B
(zh)
*
|
2007-02-16 |
2011-08-17 |
江苏正大天晴药业股份有限公司 |
4-{6-[5-(2-氯-6-甲基苯胺甲酰基)-噻唑-2-氨基]-2-甲基嘧啶-4}-哌嗪-1-甲基磷酸二乙酯
|
BRPI0808840A2
(pt)
*
|
2007-03-12 |
2014-09-02 |
Reddy S Laborartories Ltd Dr |
Mesilato de imatinib
|
US20080234286A1
(en)
*
|
2007-03-20 |
2008-09-25 |
Chemagis Ltd. |
Stable amorphous imatinib mesylate and production process therefor
|
US7550591B2
(en)
*
|
2007-05-02 |
2009-06-23 |
Chemagis Ltd. |
Imatinib production process
|
WO2008136010A1
(en)
*
|
2007-05-07 |
2008-11-13 |
Natco Pharma Limited |
A process for the preparation of highly pure imatinib base
|
WO2008150481A2
(en)
*
|
2007-05-29 |
2008-12-11 |
Sicor Inc. |
Processes for the preparation of crystalline form beta of imatinib mesylate
|
SI2305263T1
(sl)
|
2007-06-07 |
2012-10-30 |
Novartis Ag |
Stabilizirane amorfne oblike imatinib mezilata
|
BRPI0817946A2
(pt)
|
2007-09-25 |
2015-05-05 |
Teva Pharma |
Composições de imatinibe estável
|
US20090082361A1
(en)
*
|
2007-09-26 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched imatinib
|
US8501740B2
(en)
*
|
2007-10-09 |
2013-08-06 |
Board Of Regents, The University Of Texas System |
Methods of treatment of opioid tolerance, physical dependence, pain and addiction with inhibitors of certain growth factor receptors
|
EP2225226B1
(de)
|
2007-12-26 |
2016-08-17 |
Critical Outcome Technologies, Inc. |
Verbindungen und ihre verwending in einem verfahren zur behandlung von krebs
|
BRPI0908603A2
(pt)
|
2008-03-24 |
2020-08-18 |
Novartis Ag |
inibidores de metaloprotease de matriz com base em arilsulfonamida.
|
EP2628726A1
(de)
|
2008-03-26 |
2013-08-21 |
Novartis AG |
Auf Hydroxamat basierende Hemmer von Deacetylasen B
|
ES2645689T3
(es)
|
2008-05-21 |
2017-12-07 |
Ariad Pharmaceuticals, Inc. |
Derivados de fósforo como inhibidores de quinasas
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
CN101584696A
(zh)
|
2008-05-21 |
2009-11-25 |
上海艾力斯医药科技有限公司 |
包含喹唑啉衍生物的组合物及制备方法、用途
|
WO2009158447A2
(en)
|
2008-06-27 |
2009-12-30 |
Indiana University Research And Technology Corporation |
Materials and methods for suppressing and/or treating neurofibroma and related tumors
|
DE102008031037A1
(de)
|
2008-06-30 |
2009-12-31 |
Dömling, Alexander, Priv.-Doz. Dr. |
Gleevec zur Anwedung in der Organtransplantation
|
WO2010019557A1
(en)
*
|
2008-08-12 |
2010-02-18 |
Concert Pharmaceuticals Inc. |
N-phenyl-2-pyrimidineamine derivatives
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
ES2704986T3
(es)
|
2008-10-16 |
2019-03-21 |
Celator Pharmaceuticals Inc |
Combinaciones de una camptotecina liposomal soluble en agua con cetuximab o bevacizumab
|
EP2186514B1
(de)
|
2008-11-14 |
2016-06-29 |
Kinki University |
Behandlung von malignen Peripherienervmantel-Tumoren
|
US8697702B2
(en)
|
2008-12-01 |
2014-04-15 |
Novartis Ag |
Method of optimizing the treatment of Philadelphia-positive leukemia with imatinib mesylate
|
US8486930B2
(en)
|
2008-12-18 |
2013-07-16 |
Novartis Ag |
Salts
|
DK2379497T3
(da)
|
2008-12-18 |
2013-11-25 |
Novartis Ag |
Hemifumaratsalt af 1-[4-cyclohexyl-3-trifluormethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidin-3-carboxylsyre
|
KR20110112352A
(ko)
|
2008-12-18 |
2011-10-12 |
노파르티스 아게 |
1-(4-{l-[(e)-4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노]-에틸}-2-에틸-벤질)-아제티딘-3-카르복실산의 신규한 다형체 형태
|
WO2010083617A1
(en)
|
2009-01-21 |
2010-07-29 |
Oncalis Ag |
Pyrazolopyrimidines as protein kinase inhibitors
|
PT2391366E
(pt)
|
2009-01-29 |
2013-02-05 |
Novartis Ag |
Benzimidazoles substituídos para o tratamento de astrocitomas
|
UA103918C2
(en)
|
2009-03-02 |
2013-12-10 |
Айерем Элелси |
N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
|
US8530492B2
(en)
|
2009-04-17 |
2013-09-10 |
Nektar Therapeutics |
Oligomer-protein tyrosine kinase inhibitor conjugates
|
CN102414201B
(zh)
|
2009-04-28 |
2015-10-14 |
第一三共株式会社 |
溶剂化物晶体
|
US20100330130A1
(en)
*
|
2009-05-22 |
2010-12-30 |
Actavis Group Ptc Ehf |
Substantially pure imatinib or a pharmaceutically acceptable salt thereof
|
TW201102068A
(en)
*
|
2009-06-02 |
2011-01-16 |
Novartis Ag |
Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
|
ES2475945T3
(es)
|
2009-06-26 |
2014-07-11 |
Novartis Ag |
Derivados imidazolidin-2 -ona 1,3-disustituida como inhibidores de CYP 17
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
BR112012003262A8
(pt)
|
2009-08-12 |
2016-05-17 |
Novartis Ag |
compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
|
PE20121148A1
(es)
|
2009-08-17 |
2012-09-07 |
Intellikine Llc |
Compuestos heterociclicos y usos de los mismos
|
KR20120089463A
(ko)
|
2009-08-20 |
2012-08-10 |
노파르티스 아게 |
헤테로시클릭 옥심 화합물
|
US20120149661A1
(en)
|
2009-08-26 |
2012-06-14 |
Novartis Ag |
Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
|
CZ2009570A3
(cs)
|
2009-08-26 |
2011-03-09 |
Zentiva, K. S. |
Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem
|
WO2011029915A1
(en)
|
2009-09-10 |
2011-03-17 |
Novartis Ag |
Ether derivatives of bicyclic heteroaryls
|
WO2011039782A1
(en)
*
|
2009-09-29 |
2011-04-07 |
Ind-Swift Laboratories Limited |
Processes for preparing imatinib and pharmaceutically acceptable salts thereof
|
PL389357A1
(pl)
|
2009-10-22 |
2011-04-26 |
Tomasz Koźluk |
Sole imatinibu z pochodnymi kwasów winowych i sposób ich wytwarzania
|
KR101398772B1
(ko)
|
2009-11-04 |
2014-05-27 |
노파르티스 아게 |
Mek 억제제로서 유용한 헤테로시클릭 술폰아미드 유도체
|
BR112012012210B8
(pt)
|
2009-11-23 |
2021-05-25 |
Cerulean Pharma Inc |
conjugado de (cdp)-taxano de polímero contendo ciclodextrina, composição, composição farmacêutica, forma de dosagem, kit e uso de um conjugado de cdp-taxano
|
CN102712648A
(zh)
|
2009-11-25 |
2012-10-03 |
诺瓦提斯公司 |
双环杂芳基的与苯稠合的6元含氧杂环衍生物
|
BR112012013735A2
(pt)
|
2009-12-08 |
2019-09-24 |
Novartis Ag |
derivados heterocícilicos de sulfonamida
|
CU24130B1
(es)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
Isoquinolinonas y quinazolinonas sustituidas
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
US20110178287A1
(en)
|
2010-01-19 |
2011-07-21 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
WO2011095835A1
(en)
|
2010-02-02 |
2011-08-11 |
Actavis Group Ptc Ehf |
Highly pure imatinib or a pharmaceutically acceptable salt thereof
|
CA2789989A1
(en)
|
2010-02-15 |
2011-08-18 |
Reliance Life Sciences Pvt. Ltd. |
Process for the preparation of alpha form of imatinib mesylate
|
PL390611A1
(pl)
|
2010-03-04 |
2011-09-12 |
Tomasz Koźluk |
Sposób otrzymywania polimorficznej formy alfa i nowa forma polimorficzna mesylanu imatinibu
|
EP2547671A1
(de)
*
|
2010-03-15 |
2013-01-23 |
Natco Pharma Limited |
Verfahren zur herstellung einer hochreinen kristallinen imatinib-base
|
US20110237686A1
(en)
|
2010-03-26 |
2011-09-29 |
Cerulean Pharma Inc |
Formulations and methods of use
|
EP2552915B1
(de)
|
2010-04-01 |
2017-07-19 |
Critical Outcome Technologies Inc. |
Verbindungen zur behandlung von hiv
|
WO2011130918A1
(zh)
|
2010-04-23 |
2011-10-27 |
上海百灵医药科技有限公司 |
一种伊马替尼的合成方法
|
EP2382976A1
(de)
|
2010-04-30 |
2011-11-02 |
Hiroshima University |
Verwendung von PDGF-R-Inhibitoren zur Behandlung der Lymphknotenmetastasen von Magenkrebs
|
PE20130283A1
(es)
*
|
2010-06-16 |
2013-03-25 |
Takeda Pharmaceutical |
Cristal de compuesto de amida
|
WO2011158255A1
(en)
*
|
2010-06-16 |
2011-12-22 |
Aptuit Laurus Private Limited |
Process for preparation of stable imatintb mesylate alpha form
|
US20130085161A1
(en)
|
2010-06-17 |
2013-04-04 |
Novartis Ag |
Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
|
CN102947274A
(zh)
|
2010-06-17 |
2013-02-27 |
诺瓦提斯公司 |
联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
|
EA024088B1
(ru)
|
2010-06-18 |
2016-08-31 |
КРКА, д.д., НОВО МЕСТО |
α-ФОРМА МЕЗИЛАТА ИМАТИНИБА, СПОСОБЫ ЕЕ ПОЛУЧЕНИЯ И СОДЕРЖАЩАЯ ЕЁ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
RU2013110058A
(ru)
|
2010-08-11 |
2014-09-20 |
Синтон Б.В. |
Фармацевтический гранулят, содержащий иматиниба мезилат
|
TR201007005A2
(tr)
|
2010-08-23 |
2011-09-21 |
Mustafa Nevzat İlaç Sanayi̇i̇ A.Ş. |
İmatinib baz üretim yöntemi
|
WO2012027716A1
(en)
|
2010-08-27 |
2012-03-01 |
Collabrx, Inc. |
Method to treat melanoma in braf inhibitor-resistant subjects
|
RU2456280C2
(ru)
*
|
2010-08-27 |
2012-07-20 |
Общество с ограниченной ответственностью "Химфармресурс" |
Кристаллическая n-модификация 4-[(4-метил-1-пиперазинил)метил]-n-[4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]-амино]-фенил] бензамида метансульфоната, способ ее получения и фармацевтическая композиция на ее основе
|
CN103108871B
(zh)
|
2010-09-16 |
2014-09-10 |
诺华股份有限公司 |
17α-羟化酶/C17,20-裂合酶抑制剂
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
CN102477031B
(zh)
*
|
2010-11-30 |
2015-07-15 |
浙江九洲药业股份有限公司 |
一种甲磺酸伊马替尼α晶型的制备方法
|
TR201010618A2
(tr)
|
2010-12-20 |
2012-07-23 |
Bi̇lgi̇ç Mahmut |
İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi
|
CA2822565A1
(en)
|
2010-12-21 |
2012-06-28 |
Novartis Ag |
Bi-heteroaryl compounds as vps34 inhibitors
|
WO2012090221A1
(en)
|
2010-12-29 |
2012-07-05 |
Cadila Healthcare Limited |
Novel salts of imatinib
|
EP2673277A1
(de)
|
2011-02-10 |
2013-12-18 |
Novartis AG |
[1, 2, 4] triazolo [4, 3]pyridazinverbindungen als inhibitoren dec-met-tyrosinkinase
|
CN102146073A
(zh)
*
|
2011-02-23 |
2011-08-10 |
江苏先声药物研究有限公司 |
一种伊玛替尼甲烷磺酸盐α晶型新的制备方法
|
CN102649785B
(zh)
*
|
2011-02-23 |
2015-08-19 |
江苏先声药物研究有限公司 |
一种伊玛替尼甲烷磺酸盐β晶型的制备方法
|
EP2678016B1
(de)
|
2011-02-23 |
2016-08-10 |
Intellikine, LLC |
Heterocyclische verbindungen und ihre verwendung
|
CN103998040B
(zh)
|
2011-03-04 |
2017-03-29 |
江苏康缘药业股份有限公司 |
炔基取代的喹唑啉化合物及其使用方法
|
CN103492390A
(zh)
|
2011-03-08 |
2014-01-01 |
诺瓦提斯公司 |
氟苯基双环杂芳基化合物
|
PL394169A1
(pl)
|
2011-03-09 |
2012-09-10 |
Adamed Spółka Z Ograniczoną Odpowiedzialnością |
Kompozycja farmaceutyczna metanosulfonianu imatinibu do napełniania jednostkowych postaci dawkowania oraz sposób jej wytwarzania
|
US8912325B2
(en)
|
2011-03-31 |
2014-12-16 |
Ind-Swift Laboratories Limited |
Process for preparation of imatinib and its mesylate salt
|
BR112013027395A2
(pt)
|
2011-04-28 |
2017-01-17 |
Novartis Ag |
inibidores de 17alfa-hidroxilase/c17,20-liase
|
CN103501612B
(zh)
|
2011-05-04 |
2017-03-29 |
阿里亚德医药股份有限公司 |
抑制表皮生长因子受体导致的癌症中细胞增殖的化合物
|
WO2012155339A1
(zh)
|
2011-05-17 |
2012-11-22 |
江苏康缘药业股份有限公司 |
4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
|
JP6038128B2
(ja)
|
2011-06-03 |
2016-12-07 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
|
EA201391820A1
(ru)
|
2011-06-09 |
2014-12-30 |
Новартис Аг |
Гетероциклические сульфонамидные производные
|
WO2012175487A1
(en)
|
2011-06-20 |
2012-12-27 |
Novartis Ag |
Cyclohexyl isoquinolinone compounds
|
WO2012175520A1
(en)
|
2011-06-20 |
2012-12-27 |
Novartis Ag |
Hydroxy substituted isoquinolinone derivatives
|
US9750700B2
(en)
|
2011-06-22 |
2017-09-05 |
Natco Pharma Limited |
Imatinib mesylate oral pharmaceutical composition and process for preparation thereof
|
EP2723740A1
(de)
|
2011-06-27 |
2014-04-30 |
Novartis AG |
Feststoffformen und salze von tetrahydro-pyrido-pyrimidin- derivaten
|
ITMI20111309A1
(it)
|
2011-07-14 |
2013-01-15 |
Italiana Sint Spa |
Procedimento di preparazione di imatinib mesilato
|
CN102321070B
(zh)
*
|
2011-07-27 |
2013-05-22 |
江苏先声药物研究有限公司 |
反溶剂重结晶法制备伊玛替尼甲烷磺酸盐α晶型
|
AU2012310168B2
(en)
|
2011-09-15 |
2015-07-16 |
Novartis Ag |
6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
|
MX2014005130A
(es)
|
2011-10-28 |
2014-08-27 |
Novartis Ag |
Metodo para tratar tumores del estroma gastrointestinal.
|
WO2013063003A1
(en)
|
2011-10-28 |
2013-05-02 |
Novartis Ag |
Method of treating gastrointestinal stromal tumors
|
JP6096205B2
(ja)
|
2011-11-01 |
2017-03-15 |
モッドジーン リミテッド ライアビリティ カンパニーModgene,Llc |
低減されたタンパク質キナーゼ阻害を呈するイマチニブ誘導体の使用
|
CN104080787B
(zh)
|
2011-11-29 |
2016-09-14 |
诺华股份有限公司 |
吡唑并吡咯烷化合物
|
US9408885B2
(en)
|
2011-12-01 |
2016-08-09 |
Vib Vzw |
Combinations of therapeutic agents for treating melanoma
|
EP2604596A1
(de)
|
2011-12-16 |
2013-06-19 |
Deva Holding Anonim Sirketi |
Polymorphe von Imatinib
|
CN104011045B
(zh)
|
2011-12-22 |
2016-08-24 |
诺华股份有限公司 |
二氢苯并噁嗪和二氢吡啶并噁嗪衍生物
|
EP2794594A1
(de)
|
2011-12-22 |
2014-10-29 |
Novartis AG |
Chinolinderivate
|
US20140357633A1
(en)
|
2011-12-23 |
2014-12-04 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
BR112014015442A8
(pt)
|
2011-12-23 |
2017-07-04 |
Novartis Ag |
compostos e composições para inibir a interação de bcl2 com parceiros de ligação
|
EP2794588A1
(de)
|
2011-12-23 |
2014-10-29 |
Novartis AG |
Verbindungen zur hemmung der interaktion von bcl2 mit bindungspartnern
|
EP2794590A1
(de)
|
2011-12-23 |
2014-10-29 |
Novartis AG |
Verbindungen zur hemmung der interaktion von bcl2 mit bindungspartnern
|
CN104125954A
(zh)
|
2011-12-23 |
2014-10-29 |
诺华股份有限公司 |
用于抑制bcl2与结合配偶体相互作用的化合物
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
PL226174B1
(pl)
|
2011-12-30 |
2017-06-30 |
Inst Farm |
Polaczenie analogu witaminy D z imatinibem do stosowania w leczeniu skojarzonym niedrobnokomorkowego raka pluc
|
US8815926B2
(en)
|
2012-01-26 |
2014-08-26 |
Novartis Ag |
Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
|
AU2013223749A1
(en)
|
2012-02-21 |
2014-09-11 |
Sun Pharmaceutical Industries Limited |
Stable dosage forms of imatinib mesylate
|
CN102617549A
(zh)
*
|
2012-03-02 |
2012-08-01 |
瑞阳制药有限公司 |
甲磺酸伊马替尼β晶型的制备方法
|
IN2012DE00728A
(de)
|
2012-03-13 |
2015-08-21 |
Fresenius Kabi Oncology Ltd |
|
GB201204810D0
(en)
|
2012-03-20 |
2012-05-02 |
Pharos Pharmaceutical Oriented Services Ltd |
Pharmaceutical compositions
|
JP2015512425A
(ja)
|
2012-04-03 |
2015-04-27 |
ノバルティス アーゲー |
チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
|
CN102633775B
(zh)
*
|
2012-04-06 |
2013-07-17 |
江南大学 |
一种甲磺酸伊马替尼α晶型的制备方法
|
CN102617552A
(zh)
*
|
2012-04-06 |
2012-08-01 |
江南大学 |
一种制备α晶型甲磺酸伊马替尼的结晶方法
|
JP2013216644A
(ja)
*
|
2012-04-11 |
2013-10-24 |
Takada Seiyaku Kk |
イマチニブメシル酸塩経口投与製剤
|
WO2013169401A1
(en)
|
2012-05-05 |
2013-11-14 |
Ariad Pharmaceuticals, Inc. |
Compounds for inhibiting cell proliferation in egfr-driven cancers
|
EP2855483B1
(de)
|
2012-05-24 |
2017-10-25 |
Novartis AG |
Pyrrolopyrrolidinonverbindungen
|
JP6427097B2
(ja)
|
2012-06-15 |
2018-11-21 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. |
癌を処置するための組成物および該組成物を製造するための方法
|
EP2864313A1
(de)
|
2012-06-22 |
2015-04-29 |
Basf Se |
Mehrkomponentenkristalle mit imatinib-mesilat und ausgewählte co-kristall-former
|
KR101242955B1
(ko)
*
|
2012-06-25 |
2013-03-12 |
제일약품주식회사 |
이마티닙 메실레이트 결정형 α의 제조 방법
|
US20150202203A1
(en)
|
2012-07-11 |
2015-07-23 |
Novartis Ag |
Method of Treating Gastrointestinal Stromal Tumors
|
WO2014016848A2
(en)
|
2012-07-24 |
2014-01-30 |
Laurus Labs Private Limited |
Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
|
ES2656091T3
(es)
|
2012-07-27 |
2018-02-23 |
Izumi Technology, Llc. |
Composiciones de inhibidores de eflujo y métodos de tratamiento que las utilizan
|
CN103570677B
(zh)
*
|
2012-08-02 |
2017-03-01 |
广东东阳光药业有限公司 |
一种α晶型甲磺酸伊马替尼的制备方法
|
US9738643B2
(en)
|
2012-08-06 |
2017-08-22 |
Duke University |
Substituted indazoles for targeting Hsp90
|
WO2014041551A1
(en)
|
2012-09-14 |
2014-03-20 |
Natco Pharma Limited |
Formulation comprising imatinib as oral solution
|
EP2902028A1
(de)
|
2012-09-28 |
2015-08-05 |
Hangzhou Bensheng Pharmaceutical Co., Ltd. |
Wirkstoffzusammensetzung zur behandlung von tumoren und anwendung davon
|
US9439903B2
(en)
|
2012-10-25 |
2016-09-13 |
Cadila Healthcare Limited |
Process for the preparation of amorphous imatinib mesylate
|
EP3919069A1
(de)
|
2012-11-05 |
2021-12-08 |
Dana-Farber Cancer Institute, Inc. |
Xbp1-, cd138- und cs1-peptide, pharmazeutische zusammensetzungen mit den peptiden und verfahren zur verwendung derartiger peptide sowie zusammensetzungen
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫-吡啶并-□衍生物之固體形式
|
EP2749269A1
(de)
|
2012-12-31 |
2014-07-02 |
Deva Holding Anonim Sirketi |
Verfahren zur Herstellung von Adsorbaten von Imatinib
|
EP2749557A1
(de)
|
2012-12-31 |
2014-07-02 |
Deva Holding Anonim Sirketi |
Verfahren zur Herstellung von alpha-Polymorphe Form von Imatinib Mesylat aus IPA and THF-Solvaten von Imatinib Mesylat
|
EP2749271A1
(de)
|
2012-12-31 |
2014-07-02 |
Deva Holding Anonim Sirketi |
Optimiertes Verfahren zur herstellung und pharmazeutische zusammensetzung von Imatinib
|
US9556180B2
(en)
|
2013-01-22 |
2017-01-31 |
Novartis Ag |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
|
WO2014115077A1
(en)
|
2013-01-22 |
2014-07-31 |
Novartis Ag |
Substituted purinone compounds
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
DK2958943T3
(da)
|
2013-02-20 |
2019-12-09 |
Univ Pennsylvania |
Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor
|
GB201304699D0
(en)
|
2013-03-15 |
2013-05-01 |
Remedica Ltd |
Pharmaceutical compositions
|
CA2906542A1
(en)
|
2013-03-15 |
2014-09-25 |
Intellikine, Llc |
Combination of kinase inhibitors and uses thereof
|
WO2014155268A2
(en)
|
2013-03-25 |
2014-10-02 |
Novartis Ag |
Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
ES2683361T3
(es)
|
2013-05-14 |
2018-09-26 |
Hetero Research Foundation |
Composiciones de Imatinib
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
US20150044288A1
(en)
|
2013-07-31 |
2015-02-12 |
Windward Pharma, Inc. |
Aerosol tyrosine kinase inhibitor compounds and uses thereof
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
AU2014321419B2
(en)
|
2013-09-22 |
2017-06-15 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
AU2014336016B2
(en)
|
2013-10-17 |
2019-12-19 |
Sartar Therapeutics Ltd |
Compositions comprising phosphodiesterase inhibitors for use in the treatment of a solid tumor in a human patient
|
US9636340B2
(en)
|
2013-11-12 |
2017-05-02 |
Ayyappan K. Rajasekaran |
Kinase inhibitors
|
WO2015084804A1
(en)
|
2013-12-03 |
2015-06-11 |
Novartis Ag |
Combination of mdm2 inhibitor and braf inhibitor and their use
|
WO2015110949A1
(en)
|
2014-01-22 |
2015-07-30 |
Novartis Ag |
Imatinib as cholesterol decreasing agent
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
CN103800671B
(zh)
*
|
2014-02-11 |
2016-02-10 |
王思成 |
一种治疗阿弗他溃疡的中药制剂
|
EP3116909B1
(de)
|
2014-03-14 |
2019-11-13 |
Novartis Ag |
Antikörpermoleküle gegen lag-3 und verwendungen davon
|
US10000469B2
(en)
|
2014-03-25 |
2018-06-19 |
Duke University |
Heat shock protein 70 (hsp-70) receptor ligands
|
WO2015145388A2
(en)
|
2014-03-27 |
2015-10-01 |
Novartis Ag |
Methods of treating colorectal cancers harboring upstream wnt pathway mutations
|
WO2015148867A1
(en)
|
2014-03-28 |
2015-10-01 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
CA2944401A1
(en)
|
2014-04-03 |
2015-10-08 |
Invictus Oncology Pvt. Ltd. |
Supramolecular combinatorial therapeutics
|
EP2927223B1
(de)
|
2014-04-04 |
2016-06-29 |
F.I.S.- Fabbrica Italiana Sintetici S.p.A. |
Verfahren zur herstellung von imatinib und salzen davon, frei von genotoxischer verunreinigung f
|
CN104974133B
(zh)
*
|
2014-04-09 |
2018-04-27 |
石药集团中奇制药技术(石家庄)有限公司 |
一种甲磺酸伊马替尼晶型及其制备方法
|
CN104055745A
(zh)
*
|
2014-06-11 |
2014-09-24 |
连云港杰瑞药业有限公司 |
一种甲磺酸伊马替尼片的制备方法
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
JP6526789B2
(ja)
|
2014-07-31 |
2019-06-05 |
ノバルティス アーゲー |
組み合わせ療法
|
PT3524595T
(pt)
|
2014-08-28 |
2022-09-19 |
Eisai R&D Man Co Ltd |
Derivado de quinolina altamente puro e método para produção do mesmo
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
WO2016061142A1
(en)
|
2014-10-14 |
2016-04-21 |
Novartis Ag |
Antibody molecules to pd-l1 and uses thereof
|
PT3209647T
(pt)
|
2014-10-21 |
2020-09-10 |
Ariad Pharma Inc |
Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidino-2,4-diamina
|
US20170340733A1
(en)
|
2014-12-19 |
2017-11-30 |
Novartis Ag |
Combination therapies
|
SI3263106T1
(sl)
|
2015-02-25 |
2024-02-29 |
Eisai R&D Management Co., Ltd. |
Postopek zatiranja grenkobe derivata kinolina
|
AU2015384801B2
(en)
|
2015-03-04 |
2022-01-06 |
Eisai R&D Management Co., Ltd. |
Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
|
WO2016145102A1
(en)
|
2015-03-10 |
2016-09-15 |
Aduro Biotech, Inc. |
Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
|
CN104817536A
(zh)
*
|
2015-04-14 |
2015-08-05 |
江苏豪森药业股份有限公司 |
适合药用的甲磺酸伊马替尼非针状α晶型及其制备方法
|
AU2016279474B2
(en)
|
2015-06-16 |
2021-09-09 |
Eisai R&D Management Co., Ltd. |
Anticancer agent
|
CN108025051B
(zh)
|
2015-07-29 |
2021-12-24 |
诺华股份有限公司 |
包含抗pd-1抗体分子的联合疗法
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
EP3317301B1
(de)
|
2015-07-29 |
2021-04-07 |
Novartis AG |
Kombinationstherapien mit antikörpermolekülen gegen lag-3
|
JP2018527362A
(ja)
|
2015-09-11 |
2018-09-20 |
サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. |
置換されたヘテロアリール化合物および使用方法
|
EP4046655A1
(de)
|
2015-11-03 |
2022-08-24 |
Janssen Biotech, Inc. |
Spezifisch an pd-1 bindende antikörper und deren verwendungen
|
WO2017078647A1
(en)
|
2015-11-05 |
2017-05-11 |
Koçak Farma Ilaç Ve Kimya Sanayi Anonim Şirketi |
Pharmaceutical compositions of imatinib
|
CN105503825B
(zh)
*
|
2015-12-16 |
2019-01-11 |
齐鲁天和惠世制药有限公司 |
一种甲磺酸伊马替尼β晶型的制备方法
|
WO2017106656A1
(en)
|
2015-12-17 |
2017-06-22 |
Novartis Ag |
Antibody molecules to pd-1 and uses thereof
|
SG11201805331QA
(en)
|
2015-12-24 |
2018-07-30 |
Takeda Pharmaceuticals Co |
Cocrystal, production method thereof, and medicament containing cocrystal
|
EA035891B1
(ru)
|
2016-01-25 |
2020-08-27 |
КРКА, д.д., НОВО МЕСТО |
Быстродиспергируемая фармацевтическая композиция, включающая ингибитор тирозинкиназы
|
WO2017162884A1
(en)
|
2016-03-25 |
2017-09-28 |
Ab Science |
Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
|
US11261187B2
(en)
|
2016-04-22 |
2022-03-01 |
Duke University |
Compounds and methods for targeting HSP90
|
EP3257499A1
(de)
|
2016-06-17 |
2017-12-20 |
Vipharm S.A. |
Verfahren zur herstellung von imatinib methansulfonat kapseln
|
EP3507367A4
(de)
|
2016-07-05 |
2020-03-25 |
Aduro BioTech, Inc. |
Cyclisches dinukleotidverbindungen mit eingeschlossenen nukleinsäuren und verwendungen davon
|
WO2018039203A1
(en)
|
2016-08-23 |
2018-03-01 |
Oncopep, Inc. |
Peptide vaccines and durvalumab for treating multiple myeloma
|
EP3503914A1
(de)
|
2016-08-23 |
2019-07-03 |
Oncopep, Inc. |
Peptidimpfstoffe und durvalumab zur behandlung von brustkrebs
|
CN110036033B
(zh)
|
2016-09-27 |
2023-12-08 |
森罗治疗公司 |
嵌合吞噬受体分子
|
US10927083B2
(en)
|
2016-09-29 |
2021-02-23 |
Duke University |
Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
|
US10207998B2
(en)
|
2016-09-29 |
2019-02-19 |
Duke University |
Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
|
WO2018074409A1
(ja)
|
2016-10-17 |
2018-04-26 |
Delta-Fly Pharma株式会社 |
慢性骨髄性白血病を治療又は寛解するための医薬組成物
|
EP3539138B1
(de)
|
2016-11-11 |
2021-05-19 |
Curium US LLC |
Verfahren zur erzeugung von germanium-68 mit reduzierten flüchtigen stoffen
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
US20200172628A1
(en)
|
2017-06-22 |
2020-06-04 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
KR20200100598A
(ko)
|
2017-09-26 |
2020-08-26 |
세로 테라퓨틱스, 인코포레이티드 |
키메라 포식작용 수용체 분자 및 사용 방법
|
WO2019083960A1
(en)
|
2017-10-24 |
2019-05-02 |
Oncopep, Inc. |
PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
|
CA3079422A1
(en)
|
2017-10-24 |
2019-05-02 |
Oncopep, Inc. |
Peptide vaccines and pembrolizumab for treating breast cancer
|
US10683297B2
(en)
|
2017-11-19 |
2020-06-16 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
AU2017444054B2
(en)
|
2017-12-21 |
2021-10-07 |
Hefei Institutes Of Physical Science, Chinese Academy Of Sciences |
Class of pyrimidine derivative kinase inhibitors
|
AU2019209960B2
(en)
|
2018-01-20 |
2023-11-23 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
EP3774906A1
(de)
|
2018-03-28 |
2021-02-17 |
Cero Therapeutics, Inc. |
Chimäre tim4-rezeptoren und verwendungen davon
|
AU2019243153A1
(en)
|
2018-03-28 |
2020-10-01 |
Cero Therapeutics, Inc. |
Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof
|
EP3774865A1
(de)
|
2018-03-28 |
2021-02-17 |
Cero Therapeutics, Inc. |
Zelluläre immunotherapiezusammensetzungen und ihre verwendungen
|
TW202015726A
(zh)
|
2018-05-30 |
2020-05-01 |
瑞士商諾華公司 |
Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法
|
WO2020023628A1
(en)
|
2018-07-24 |
2020-01-30 |
Hygia Pharmaceuticals, Llc |
Compounds, derivatives, and analogs for cancer
|
BR112021011894A2
(pt)
|
2018-12-21 |
2021-09-08 |
Daiichi Sankyo Company, Limited |
Composição farmacêutica
|
EP4007585A4
(de)
|
2019-08-02 |
2023-11-08 |
OneHealthCompany, Inc. |
Behandlung von krebserkrankungen beim hund
|
CN114502590A
(zh)
|
2019-09-18 |
2022-05-13 |
诺华股份有限公司 |
Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
|
EP4038097A1
(de)
|
2019-10-03 |
2022-08-10 |
Cero Therapeutics, Inc. |
Chimäre tim4-rezeptoren und verwendungen davon
|
US20220395553A1
(en)
|
2019-11-14 |
2022-12-15 |
Cohbar, Inc. |
Cxcr4 antagonist peptides
|
WO2021185844A1
(en)
|
2020-03-16 |
2021-09-23 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
WO2021233534A1
(en)
|
2020-05-20 |
2021-11-25 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
US20230285576A1
(en)
|
2020-08-05 |
2023-09-14 |
Ellipses Pharma Ltd |
Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
|
WO2022036265A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Chimeric tim receptors and uses thereof
|
WO2022036285A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
|
WO2022036287A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Anti-cd72 chimeric receptors and uses thereof
|
WO2022047259A1
(en)
|
2020-08-28 |
2022-03-03 |
California Institute Of Technology |
Synthetic mammalian signaling circuits for robust cell population control
|
TW202237638A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
烏苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法
|
AU2022227021A1
(en)
|
2021-02-26 |
2023-09-21 |
Kelonia Therapeutics, Inc. |
Lymphocyte targeted lentiviral vectors
|
KR20240119868A
(ko)
|
2021-07-28 |
2024-08-06 |
세로 테라퓨틱스, 인코포레이티드 |
키메라 tim4 수용체 및 이의 용도
|
CN114957206B
(zh)
*
|
2022-04-11 |
2024-02-27 |
中国药科大学 |
伊马替尼共晶及其制备方法
|
WO2024030441A1
(en)
|
2022-08-02 |
2024-02-08 |
National University Corporation Hokkaido University |
Methods of improving cellular therapy with organelle complexes
|